Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Announces Issuance of Stock Options

  • March 20, 2018December 22, 2020
  • by aaronbb

CALGARY, Alberta, March 20, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has issued an aggregate of 2,250,000 options to purchase common shares of the Company to certain directors, officers, consultants and employees in accordance with the Company’s stock option plan.   The options are exercisable at a price of $0.50 per common share and expire five years from the date of grant, being March 19, 2023.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease.  XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease.  Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.XORTX.com.

For further information, please contact: Erik Matthews, Corporate Communications & Investor Relations
+1-747-203-5240 or erik@xortx.com /  ray@xortx.com

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Related

XORTX Therapeutics Provides Corporate Update
XORTX Announces PKD Foundation Collaboration

Press Releases

  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Participating in WuXI Healthcare Forum March 1, 2021
  • XORTX to Present at BIO CEO and Investor Conference February 17, 2021
  • XORTX Closes Over Subscribed Private Placement February 10, 2021

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress